We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GSK to Report First-Quarter Earnings: Is a Beat in Store?
Read MoreHide Full Article
We expect GSK plc (GSK - Free Report) to surpass expectations when it reports first-quarter 2025 earnings on April 30, before the opening bell. The company’s earnings beat estimates by 11.32% in the last reported quarter.
The Zacks Consensus Estimate for sales and earnings is pegged at $9.54 billion and $1.08 per American depositary share (ADS), respectively. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Factors Shaping GSK’s Upcoming Results
GSK reports financial figures under three segments — Specialty Medicines, Vaccines and General Medicines.
In the first quarter, higher sales of newer products like Cabenuva, Juluca, Dovato, Nucala, Ojjaara, Jemperli and Trelegy Ellipta are likely to have offset the decline in sales of older HIV drugs and respiratory medicines due to generic erosion and competitive pressure.
In HIV, the strong sales growth trend witnessed in recent quarters of the two-drug regimens, Dovato and J&J (JNJ - Free Report) -partnered Juluca, and long-acting regimens, Cabenuva and Apretude, might have more than offset losses in sales of the three-drug regimens in the to-be-reported quarter. Our model estimates sales from the HIV portfolio to be £1.71 billion.
Sales of GSK’s vaccine segment have been declining in the past few quarters, due to lower sales of key vaccines Shingrix (shingles vaccine) and Arexvy (RSV vaccine). While Shingrix sales have been affected due to lower demand in the U.S. and International markets, the fall in Arexvy sales can be attributed to the restrictive recommendation issued by the U.S. CDC last year for individuals in the 60-74 age bracket. We expect this trend to have continued in the to-be-reported quarter.
Our model predicts the overall sales from the vaccine segment to be about £2.2 billion. This includes Shingrix and Arexvy sales of around £908 million and £155 million, respectively. We expect GSK to add £843 million from the sale of its Established vaccines.
Oncology sales are likely to have witnessed growth backed by the rising demand for PD-1 inhibitor Jemperli and PARP inhibitor Zejula sales, coupled with the recently-launched blood cancer drug Ojjaara. Our model expects the Oncology portfolio to report about £380 million in sales.
Other key drivers of top-line growth in GSK’s portfolio include respiratory drugs Trelegy Ellipta and Nucala. Our model expects Trelegy and Nucala to report about £677 million and £403 million, respectively, in sales.
GSK’s Earnings Surprise History
The British drugmaker’s performance has been impressive. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.44%.
Year to date, GSK’s shares have gained 11% against the industry’s 5% decline.
Image Source: Zacks Investment Research
What Our Model Predicts for GSK
Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of delivering an earnings beat. This is the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some other biotech stocks that have the right combination of elements to beat on earnings this time around:
argenx (ARGX - Free Report) has an Earnings ESP of +10.92% and a Zacks Rank #2 at present.
argenx stock failed to deliver any returns in the year-to-date period. It beat on earnings in two of the last four quarters and missed in the other two, delivering an average surprise of 345.11%.
CytomX Therapeutics (CTMX - Free Report) has an Earnings ESP of +38.89% and a Zacks Rank #2 at present.
CytomX Therapeutics’ shares have plunged 31% year to date. CytomXbeat on earnings in three of the trailing four quarters and missed in the other one, delivering an average surprise of 180.70%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GSK to Report First-Quarter Earnings: Is a Beat in Store?
We expect GSK plc (GSK - Free Report) to surpass expectations when it reports first-quarter 2025 earnings on April 30, before the opening bell. The company’s earnings beat estimates by 11.32% in the last reported quarter.
The Zacks Consensus Estimate for sales and earnings is pegged at $9.54 billion and $1.08 per American depositary share (ADS), respectively. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Factors Shaping GSK’s Upcoming Results
GSK reports financial figures under three segments — Specialty Medicines, Vaccines and General Medicines.
In the first quarter, higher sales of newer products like Cabenuva, Juluca, Dovato, Nucala, Ojjaara, Jemperli and Trelegy Ellipta are likely to have offset the decline in sales of older HIV drugs and respiratory medicines due to generic erosion and competitive pressure.
In HIV, the strong sales growth trend witnessed in recent quarters of the two-drug regimens, Dovato and J&J (JNJ - Free Report) -partnered Juluca, and long-acting regimens, Cabenuva and Apretude, might have more than offset losses in sales of the three-drug regimens in the to-be-reported quarter. Our model estimates sales from the HIV portfolio to be £1.71 billion.
Sales of GSK’s vaccine segment have been declining in the past few quarters, due to lower sales of key vaccines Shingrix (shingles vaccine) and Arexvy (RSV vaccine). While Shingrix sales have been affected due to lower demand in the U.S. and International markets, the fall in Arexvy sales can be attributed to the restrictive recommendation issued by the U.S. CDC last year for individuals in the 60-74 age bracket. We expect this trend to have continued in the to-be-reported quarter.
Our model predicts the overall sales from the vaccine segment to be about £2.2 billion. This includes Shingrix and Arexvy sales of around £908 million and £155 million, respectively. We expect GSK to add £843 million from the sale of its Established vaccines.
Oncology sales are likely to have witnessed growth backed by the rising demand for PD-1 inhibitor Jemperli and PARP inhibitor Zejula sales, coupled with the recently-launched blood cancer drug Ojjaara. Our model expects the Oncology portfolio to report about £380 million in sales.
Other key drivers of top-line growth in GSK’s portfolio include respiratory drugs Trelegy Ellipta and Nucala. Our model expects Trelegy and Nucala to report about £677 million and £403 million, respectively, in sales.
GSK’s Earnings Surprise History
The British drugmaker’s performance has been impressive. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.44%.
GSK PLC Sponsored ADR Price and EPS Surprise
GSK PLC Sponsored ADR price-eps-surprise | GSK PLC Sponsored ADR Quote
Year to date, GSK’s shares have gained 11% against the industry’s 5% decline.
Image Source: Zacks Investment Research
What Our Model Predicts for GSK
Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of delivering an earnings beat. This is the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
GSK has an Earnings ESP of +3.16% and a Zacks Rank#3, indicating a likely beat. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Other Stocks to Consider
Here are some other biotech stocks that have the right combination of elements to beat on earnings this time around:
argenx (ARGX - Free Report) has an Earnings ESP of +10.92% and a Zacks Rank #2 at present.
argenx stock failed to deliver any returns in the year-to-date period. It beat on earnings in two of the last four quarters and missed in the other two, delivering an average surprise of 345.11%.
CytomX Therapeutics (CTMX - Free Report) has an Earnings ESP of +38.89% and a Zacks Rank #2 at present.
CytomX Therapeutics’ shares have plunged 31% year to date. CytomXbeat on earnings in three of the trailing four quarters and missed in the other one, delivering an average surprise of 180.70%.